A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.

Neuroscientists identify a CRF-neuron "switch" in the brain's BNST region that, when activated, allows for significantly faster unlearning of fear responses.

Post Traumatic Stress Disorder (PTSD) has been invoked to help explain many aspects of human behavior, including violence. The April 2 shooting at Fort Hood in Texas that left three dead and sixteen ...

MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics ...